#### FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

washington, D.C. 2052

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Saad Mark E  (Last) (First) (Middle)  3020 CALLAN ROAD					3. D	Issuer Name and Ticker or Trading Symbol     CYTORI THERAPEUTICS, INC. [ CYTX ]      Jate of Earliest Transaction (Month/Day/Year)     02/28/2011								(Ch	Direct All App Direct Market All Apples All	blicable) ctor er (give title v)	g Person(s) to I  10% ( Other below ncial Officer	Owner (specify
(Street) SAN DIEGO CA 92121 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line	e) <mark>X</mark> Forn Forn	ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person			
		Tabl	e I - Noi	n-Deriv	ative	Se	curitie	s Ac	quired	, Dis	posed o	f, or I	3enet	icial	ly Owne	ed		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)						Execution Date			Transaction Dispo		Disposed	curities Acquired (A) osed Of (D) (Instr. 3, 4			Securi Benef	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A	() or ()	Price	Transa	action(s) 3 and 4)		(1130.4)
Restricted Stock Award (Common Stock) <sup>(1)</sup> 02/28/2					3/2011	2011			A		33,500	(1)	Α	\$0	1	16,000	D	
			(	e.g., pı	uts, c		, warr	ants,	option	ıs, c	sed of, onvertib	le se	curiti	es)				1
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Expiration Date Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. : and 4)  Amount or Number of Shares		3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

# Explanation of Responses:

1. The vesting of the Restricted Stock Award depends upon the achievement of certain performance goals for the year ended December 31, 2011. Those goals include obtaining certain FDA clearance or approval, achieving a targeted revenue increase and entering in to a major collaboration for development/commercialization of the Company's products. The deadline for achieving these goals is January 1, 2012, at which time the Compensation Committee will determine the percentage of stock that will continue to vest. The shares that continue to vest will be fully vested on Jan.1, 2013.

### Remarks:

Jonathan E. Soneff, By Power of Attorney For: Mark E. Saad

03/01/2011

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.